After the bell yesterday, Provention Bio (PRVB) announced a proposed offering of common stock.

This is not déjà vu all over again.

You’ll recall, in June, the company also announced an offering immediately following the release of the breakthrough results for teplizumab in “at-risk” patients. And I publicly criticized the move (see here).

This time around? I’m ecstatic. And here’s why…


Want to keep reading? No problem! All you have to do is sign up for FREE here as a registered user. 

By doing so, you agree to receive periodic research updates from DTR and only DTR.

We will never rent, sell or share your info.